The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Gufic Biosciences Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.55% INR315.90
America/New_York / 8 mai 2024 @ 06:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 31 678 mill |
| EPS: | 8.63 |
| P/E: | 36.60 |
| Earnings Date: | May 27, 2024 |
| SharesOutstanding: | 100.28 mill |
| Avg Daily Volume: | 0.109 mill |
| RATING 2024-05-08 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 36.60 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 36.60 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR-149.52 (-147.33%) INR-465.42 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 305.67 - 326.13 ( +/- 3.24%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | INR315.90 (-0.55% ) |
| Volume | 0.0247 mill |
| Avg. Vol. | 0.109 mill |
| % of Avg. Vol | 22.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GUFICBIO.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GUFICBIO.NS
Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.